The Polyrizon Ltd. (PLRZ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Polyrizon files reports on Form 20-F and Form 6-K under the Securities Exchange Act of 1934, and these documents offer insight into its development-stage biotechnology activities, financial condition, and corporate actions.
Recent Form 6-K filings incorporate press releases on key scientific and product milestones, such as preclinical results for PL-14 Allergy Blocker and PL-16 Viral Blocker, as well as data from the company’s intranasal naloxone hydrogel program within the Trap & Target™ platform. Other 6-K submissions include interim condensed financial statements, management’s discussion and analysis, and notices related to shareholder meetings and voting matters.
Filings also document capital structure and listing-related events. For example, Polyrizon has reported a reverse share split of its ordinary shares at a 1-for-6 ratio and has furnished a press release noting that it regained compliance with Nasdaq listing requirements. These disclosures help investors understand changes in share count, adjustments to warrants and options, and the company’s listing status.
Through Stock Titan, users can review Polyrizon’s 6-K reports and related exhibits, including financial statements, regulatory correspondence summaries, and scientific press releases that are incorporated by reference into registration statements on Form S-8 and Form F-3. AI-powered tools on the platform can assist in summarizing lengthy filings, highlighting key sections on topics such as product development, regulatory interactions with the FDA, and corporate approvals, helping readers navigate Polyrizon’s SEC reporting history more efficiently.
Polyrizon Ltd. announced it has filed a new U.S. divisional patent application titled “Mucoadhesive Polymers for Nasal Drug Delivery.” The application is part of the company’s existing U.S. patent family and seeks additional protection for distinct aspects and applications of its mucoadhesive technology.
The technology uses polymeric compositions designed to form a continuous and durable layer upon contact with mucosal tissue. Polyrizon describes potential use of these compositions to deliver therapeutic agents locally or systemically through mucosal tissues, including the nasal mucosa. The company said it cannot assure that a patent will issue from the pending application or that any patent issued will be advantageous.
Polyrizon Ltd. (PLRZ) registered up to 404,166 ordinary shares for resale by Armistice Capital, LLC: up to 70,833 shares issuable upon exercise of PIPE pre-funded warrants and up to 333,333 upon exercise of ordinary share warrants. Polyrizon receives no proceeds from resales. It may receive approximately $4.0 million if these warrants are exercised for cash, subject to exercise-price adjustments; any such proceeds are intended for general corporate purposes and working capital.
The warrants’ exercise prices are $0.00001 per share for the PIPE pre-funded warrants and $12.00 per share for the ordinary share warrants. Holders may not exercise if doing so would cause them and specified affiliates or related parties to beneficially own more than 9.99% of ordinary shares immediately after exercise. Polyrizon had 2,428,604 ordinary shares outstanding as of September 28, 2026.
For the six months ended June 30, 2026, unaudited net loss was $1.424 million, compared with a $177,000 loss for the six months ended June 30, 2025; cash and cash equivalents were $8.410 million as of June 30, 2026. The development-stage biotech company said NASARIX received central Institutional Review Board approval to begin its first human clinical trial.
Polyrizon Ltd. reported a $1.424 million net loss for the six months ended June 30, 2026, versus $177,000 for the same six-month period in 2025. Research and development expenses were $1.382 million versus $776,000, and general and administrative expenses were $2.942 million versus $1.709 million. Net cash used in operating activities was $1.955 million versus $1.821 million; the company has not generated revenue from current operations.
The September 2026 registered direct offering and concurrent private placement closed September 4, generating approximately $4.0 million in gross proceeds before fees and expenses. The registered direct offering included 232,500 ordinary shares and 30,000 pre-funded warrants; the private placement included 70,833 pre-funded warrants and 333,333 ordinary share warrants. Exercise is barred if a holder’s beneficial ownership would exceed 9.99% of ordinary shares outstanding immediately after exercise; ordinary share warrants have a five-year term. As of June 30, cash and short-term bank deposits totaled approximately $11.4 million, and long-term deposits totaled approximately $6.1 million. Management believes existing cash and cash equivalents will fund operations through March 2030. Polyrizon also reported central IRB approval to begin its first human clinical trial.
Polyrizon Ltd. (PLRZ), an Israeli development-stage biotech focused on nasal hydrogel barrier and drug-delivery sprays, is registering for resale up to 404,166 Ordinary Shares. These shares are issuable upon exercise of September 2026 private-placement warrants held by a single selling shareholder.
No Ordinary Shares are being sold by Polyrizon itself, and it will not receive proceeds from resales. The underlying September 2026 Ordinary Share Warrants and PIPE Pre-Funded Warrants are exercisable at $12.00 and $0.00001 per share, respectively, potentially providing about $4.0 million in cash to the company if exercised for cash. Ordinary shares outstanding were 2,402,067 as of September 17, 2026, and would be 2,806,233 if all registered warrants are exercised.
Polyrizon Ltd. (PLRZ), an Israel-based biotechnology company, filed a Form D for a new exempt offering under Rule 506(b) of Regulation D. The offering began on September 3, 2026 and relates to warrants and the shares issuable upon their exercise.
The company reports total securities sold of $3,999,996 with nothing remaining to be sold. The securities were issued in connection with a registered direct offering of 232,500 shares and pre-funded warrants for 30,000 shares, and a private placement of pre-funded warrants for 70,833 shares and warrants for 333,333 shares. Aegis Capital Corp. is entitled to an 8.0% cash placement fee on gross proceeds plus $75,000 for legal fees, and Polyrizon intends to use net proceeds for general corporate purposes including operations, capital expenditures, business and technology development, and strategic opportunities.
Polyrizon Ltd. (PLRZ) completed a registered direct offering and concurrent private placement with a single institutional investor, raising aggregate gross proceeds of approximately $4.0 million.
The transactions involved the sale of 333,333 Units (or Pre-Funded Units), each consisting of one Ordinary Share (or one Pre-Funded Warrant) and one Common Warrant, at $12.00 per Unit (or $11.99999 per Pre-Funded Unit). Polyrizon issued 232,500 Ordinary Shares and 30,000 Pre-Funded Warrants in the registered direct component and 70,833 PIPE Pre-Funded Warrants and 333,333 PIPE Common Warrants in the private placement. The Pre-Funded Warrants are immediately exercisable at $0.00001 per share (subject, for unregistered PIPE Pre-Funded Warrants, to registration), and the Common Warrants have a $12.00 per share exercise price. Polyrizon expects to use the net proceeds for general corporate purposes and working capital.
Polyrizon Ltd. (PLRZ) entered into definitive agreements for a combined registered direct offering and concurrent private placement with a single institutional investor, structured as 333,333 units at a combined offering price of $12.00 per unit, for expected aggregate gross proceeds of $4.0 million.
The registered direct component covers the sale of 232,500 Ordinary Shares and 30,000 pre-funded warrants, while the private placement adds 70,833 PIPE pre-funded warrants and 333,333 Ordinary Share Warrants, each warrant exercisable for one Ordinary Share. Pre-funded warrants carry a de minimis exercise price of $0.00001 and no expiration, and all warrants are subject to a 9.99% beneficial ownership cap. Aegis Capital Corp. acts as exclusive placement agent, earning an 8.0% cash fee and $75,000 for expenses. Gross proceeds are expected to support general corporate purposes, including operations, capital expenditures, business development, technology development and potential strategic acquisitions. Assuming exercise of all pre-funded warrants issued in the transactions, Ordinary Shares outstanding would total 2,806,233.
Polyrizon Ltd. (PLRZ) is conducting a shelf takedown under its Form F-3 to sell 232,500 ordinary shares at $12.00 per share and 30,000 pre-funded warrants at $11.99999 each, plus 30,000 ordinary shares underlying those pre-funded warrants. This public offering represents gross proceeds of $3,149,999.70, with placement fees of $251,999.98 and proceeds before expenses of $2,897,999.72. In a concurrent private placement, the company is also issuing 70,833 additional pre-funded warrants and 333,333 unregistered ordinary share warrants, each exercisable at $12.00 per share for five years. Ordinary shares outstanding were 2,139,567 as of September 2, 2026 and are expected to be 2,402,067 after this offering, assuming full exercise of the registered pre-funded warrants. Net proceeds from this offering and the concurrent private placement are estimated at about $3.5 million, to be used for general corporate purposes, including operations, R&D, and potential strategic acquisitions.
Polyrizon Ltd. (PLRZ) reports an operational milestone for its NASARIX™ Allergy Blocker (PL-14) program, having completed contracting with all five U.S. clinical sites for its first-in-human study. The report also incorporates portions of this update by reference into existing Form S-8 and Form F-3 registration statements.
The planned prospective, multicenter, randomized, single-blind, two-arm trial will enroll up to 120 patients with seasonal allergic rhinitis, randomized 1:1 to NASARIX™ or isotonic saline nasal spray. Primary efficacy will be measured by mean daily reflective Total Nasal Symptom Score over the first 14 treatment days, with safety based on treatment-emergent adverse events and tolerability. Polyrizon is now moving into patient pre-screening and enrollment, timed to relevant allergy seasons.